Research

Research

Original research to investigate mechanisms of drug action in humans
Major areas of original research are (1) drug effects on potassium homeostasis (2) mechanisms of potassium handing in humans in health and disease, (3) mechanisms and treatment of postmenopausal hypertension (3) mechanisms of sodium sensitivity of blood pressure, (4) translational research in proteinuric kidney disease.

Design and conduct of phase I research studies in special populations.
We have developed special expertise in the design and conduct of pharmacokinetic, pharmacodynamic and safety studies including renal impairment, hepatic impairment, postmenopausal hypertension, elderly, women’s health, rheumatology, osteoarthritis, diabetes mellitus, and healthy volunteers. Our Clinical Pharmacology Research Unit enjoys an international reputation as a premier study site for conducting phase I studies in special populations.

Support of Medical School Research Infrastructure
Our Division supports the general medical school research infrastructure by functioning as a core clinical inpatient research center and providing the expertise, study design, and research bed resources to help support the work of our colleagues. We provide the resources for the support of clinical research projects across multiple Divisions in Medicine and Departments School-Wide. At any one time we are supporting 3-4 projects of our UM investigators.

Conduct of Phase I Research for Industry
The University of Miami Division of Clinical Pharmacology has been conducting Phase I, II and III clinical research for pharmaceutical and biotech companies for more than 20 years. Each year we conduct 5-6 studies in phase I renal impairment and 5-6 studies in phase I hepatic impairment. Over the years, we have developed an efficient mode of operation compatible with the expectations and time concerns of modern pharmaceutical companies. The turnaround time on IRB approvals is approximately 2-3 weeks and our contracts and agreement process can be accomplished in parallel.